Abstract:Objective: To induce potent CD8+ T-cells against glypican-3(GPC3), which is overexpressed in hepatocellular carcinoma(HCC), to suspend tumor development. Methods: Since the chemokine receptor XCR1 is selectivelyexpressed on professional cross-presenting CD8α+ dendriticcells (DCs), which have been identified as the most potentcells to induce antigen-specific CD8+ T-cell generation, weconstructed a XCL1/GPC3 fusion protein as a potential cancervaccine. The fusion gene expression and targeting of the expressed fusion protein to CD8α+ DCs were examined inmouse lymph nodes. Protein function was further examined byusing freshly isolated human lymph node cells. We immunizedthe mice subcutaneously with the XCL1/GPC3 fusion gene andmonitored the tumor growth in a diethylnitrosamine-inducedautochthonous murine HCC model with a chronic hepatitis Bvirus (HBV) infection background. The effects of the XCL1/GPC3 fusion protein were further analyzed in human HCCtissue-derived xenografts in NSG immunodeficient mice. Results: The gene-transfected cells expressed and secretedextracellular XCL1/GPC3 fusion protein, which showed strongchemotactic activity for murine CD8α+ DCs and the humanequivalent, CD141+ DCs, in vitro. Compared with the GPC3-treated cells, XCL1/GPC3 fusion protein induced more potentGPC3-specific CD8+ T-cell generation that showed higherantigen-specific cytotoxicity to the GPC3144-152 peptide. Afterimmunization with the XCL1/GPC3 fusion gene, the productswere detected in the immunization sites of mice and in theirdraining lymph nodes. The fusion proteins were mainlyfound in the CD11c+ DCs in the T-cell zones of lymph nodes.Compared with the GPC3 gene alone, immunization with theXCL1/GPC3 fusion gene generated significantly more GPC3-specific CD8+ IFN-γ-producing T-cells in the mouse livers,which could specifically eliminate GPC3-expressing tumorcells. We immunized the diethylnitrosamine-treated mice thathave a chronic HBV infection background, starting at week 4,when HCC cells were detected in the liver by histology, or atweek 14, when small liver tumors were surgically observed. Byweek 22 after diethylnitrosamine injection when all the micewere sacrificed, significantly fewer HCC cells were found inthe XCL1/GPC3-immunized mice than in the GPC3 geneimmunizedmice (P < 0.01). T-cells isolated from XCL1/GPC3-immunized mice were able to eliminate subcutaneouslytransplanted GPC3-expressing hepatoma tumors. The effectswere further enhanced in combination with injection of 200 μgof anti-PD1 antibody. More activated NK cells, NKT cells, andtype 1 innate lymphoid cells (ILC1s) were also detected in theXCL1/GPC3-immunized mice livers. In NSG immunodeficientmice with human HCC tissue-derived xenografts, the XCL1/GPC3 fusion protein-stimulated autologous T-cells were able tosuspend HCC growth. One dose of anti-PD1 further enhancedthe effect on HCC growth inhibition. Conclusions: Immunization with the XCL1/GPC3 fusion gene couldinduce potent CD8+ T-cell generation. The XCL1/GPC3 serves as apromising cancer vaccine for intervention in HCC development. DOI: 10.20892/j.issn.2095-3941.2018.S056

Gpc3 Fused to an Alpha Epitope of Hbsag Acts As an Immune Target Against Hepatocellular Carcinoma Associated with Hepatitis B Virus

GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.

Glypican‐3: A Promising Biomarker for Hepatocellular Carcinoma Diagnosis and Treatment

Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice

Re-Anchored GPC3-hAFP542-550 Fusion Protein Localizes to Hepatocellular Carcinoma Cell Membrane and Induces Cytokine Secretion by Lymphocytes

XCL1/Glypican-3 Fusion Protein Induces Potent CD8+ T-cell Generation and Enhances the Anti-Pd1 Effect to Suspend Hepatocellular Carcinoma Development

Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma

Polyclonal Antibody Production Against Rgpc3 and Their Application in Diagnosis of Hepatocellular Carcinoma

HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.

Experimental Study of Β-Gc Combined with HBsAg Gene-Modified Dendritic Cell-Based Tumor Vaccine to Hepatocellular Carcinoma by Different Immune Ways

Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma

Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma

A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma

Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma.

[Preparation of bacterial outer membrane vesicles with anti-GPC3 single-chain antibody and identification of their targeting effects on hepatocellular carcinoma]

Construction and Evaluation of GPC3-Targeted Immunotoxins As a Novel Therapeutic Modality for Hepatocellular Carcinoma

Hbcag18-27 Epitope Fused To Hiv-Tat(49-57) Adjuvanted With Cpg Odn Induces Immunotherapeutic Effects In Transgenic Mice

Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection

Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma

Prokaryote Expression of GPC3 C Terminal Protein and Prepration of Monoclonal Antibody